Screening Mongolians in France for hepatitis B, C and delta
Screens the Mongolian community in France for hepatitis B, C and delta virus infections.
Plain-language title generated from the registry record
Registry title: Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
Key facts
- Where
- Annecy, Bordeaux, Clermont-Ferrand, Créteil, Grenoble, Lille, Lyon, Rennes, Rouen, Strasbourg, and Tours, FranceSee the 11 sites
Where in France
- Centre Hospitalier Annecy GenevoisAnnecy, FranceNo longer taking part
- Centre Expert Hépatites Virales Aquitaine, CHU de BordeauxBordeaux, FranceNo longer taking part
- CHU de Clermont-FerrandClermont-Ferrand, FranceNo longer taking part
- Hôpital Henri Mondor - Assistante Publique Hopitaux de Paris (APHP)Créteil, FranceNo longer taking part
- CHU Grenoble AlpesGrenoble, FranceNo longer taking part
- CHRU LilleLille, FranceNo longer taking part
- Service d'Hépatologie, Institut d'hépatologie de Lyon, Hôpital Croix-Rousse, Hospices Civils de LyonLyon, FranceNo longer taking part
- CHRU Rennes PontchaillouRennes, FranceNo longer taking part
- CHU de RouenRouen, FranceNo longer taking part
- Hopitaux Universitaires de StrasbourgStrasbourg, FranceNo longer taking part
- CHRU BretonneauTours, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07038863
- Record updated
- 26 June 2025
- Original description
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.Read full original descriptionShow less
Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.
There is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.
Inclusion: Mongolian people; Over 15 years of age; Living in France; Majors agree to participate or minors whose parental guardians agree to their child's participation in the study.
Exclusion: People already followed for viral hepatitis, treated or not treated; Persons deprived of their liberty by a judicial or administrative decision; Adults subject to a legal protection measure (guardianship, curators); People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis.